Christina E. Henson, MD, presented “Radiation Therapy: What’s New for Localized Disease” during the 5th Annual Oklahoma Prostate & Urologic Cancers Symposium on September 13th, 2019 in Oklahoma City, Oklahoma.
How to cite: Henson, Christina E. “Expanding the Role of Surgical Management of High-Risk Prostate Cancer” September 13th, 2019. Accessed Apr 2024. https://dev.grandroundsinurology.com/radiation-therapy-whats-new-for-localized-disease/
Radiation Therapy: What’s New for Localized Disease – Summary:
Christina E. Henson, MD, describes how recent trial-based research has established new standards in prostate cancer radiotherapy. She discusses several modes of therapy, including hypofractionation, metastasis-directed therapy for treating oligometastatic disease, and pelvic nodal irradiation, noting that research has shown them to be effective treatments in a variety of disease states. Ultra-hypofractionation has been proven to have an increased therapeutic ratio compared to other methods, as well as a 5-year failure-free survival of 84% across all trials. Elective nodal radiation up to L4 or higher is now recommended to maximize treatment outcomes. Metastasis-directed therapy has been proven to help patients even with limited disease burden and should be viewed as an option in these cases, though it is not always successful.
About The 5th Annual Prostate & Urologic Cancer Symposium:
The Prostate & Urologic Cancers Symposium is held through the University of Oklahoma and the Stephenson Cancer Center to provide new insights in the treatment of prostate and urologic cancers. This single-day program consists of lectures and case discussions highlighting a multidisciplinary approach to urologic cancer care and integration of new technology in the evaluation and treatment of patients with prostate and/or urologic cancers. Dr. Henson presented this lecture during the 5th iteration of this summit in 2019.
Please visit our collection page to view additional educational activtities from this symposium.
